The need for high quality cancer care in the United States is ever increasing, but the system is in distress. An aging population will increase demand for services at a at time when rising costs, uneven accessibility, anticipated workforce shortages and a lack of evidence based cancer care delivery solutions have put the system into crisis. This was the conclusion of an Institute of Medicine (lOM) committee report which recently published a number of recommendations in Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis, Washington DC, National Academies Press, 2013. The important role for clinical trials especially in the area of comparative effectiveness research, an the translation of results into clinical practice was emphasized by the lOM committee. The new National Community Oncology Research Program (NCORP) is poised to engage this recommendation and the Columbus CCOP/NCORP with our experience in cancer care delivery research and educational programs to translate research results to care-givers is uniquely suited to this task. We have continued our reputation for innovation by adapting our existing infrastructure in the design of an integrated cancer care delivery research program involving our 3 major hospitals, coordinated by a team headed by a physician with experience in this area. Our history of extensive community interactions will enhance this effort. The Columbus CCOP/NCORP is indeed ready to join with the NCORP as we forge an innovative evidence-based, patient-centered cancer care delivery system. We are proud of our success in the past and look forward to a bright future as the Columbus NCORP.

Public Health Relevance

Although great strides have been made, there is a continuing need for the improved and efficient delivery of cancer care based on solid evidence obtained from well-designed clinical research trials. Participation in this activity by our established community consortium under the auspices of the NCORP will help to achieve the goal of cancer control in our time.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1CA189954-03
Application #
9118925
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Russo, Sandra
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
3
Fiscal Year
2016
Total Cost
$410,800
Indirect Cost
Name
Columbus Community Clinical Oncology Prg
Department
Type
DUNS #
140098778
City
Columbus
State
OH
Country
United States
Zip Code
43215
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Meropol, Neal J; Feng, Yang; Grem, Jean L et al. (2018) Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer 124:688-697
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Wagner, Lynne I; Zhao, Fengmin; Goss, Paul E et al. (2018) Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG Breast Cancer Res Treat 169:537-548
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952

Showing the most recent 10 out of 17 publications